Abstract

Dysfunction of adipocytes and adipose tissue is a primary defect in obesity and obesity-associated metabolic diseases. Interferon regulatory factor 3 (IRF3) has been implicated in adipogenesis. However, the role of IRF3 in obesity and obesity-associated disorders remains unclear. Here, we show that IRF3 expression in human adipose tissues is positively associated with insulin sensitivity and negatively associated with type 2 diabetes. In mouse pre-adipocytes, deficiency of IRF3 results in increased expression of PPARγ and PPARγ-mediated adipogenic genes, leading to increased adipogenesis and altered adipocyte functionality. The IRF3 knockout (KO) mice develop obesity, insulin resistance, glucose intolerance, and eventually type 2 diabetes with aging, which is associated with the development of white adipose tissue (WAT) inflammation. Increased macrophage accumulation with M1 phenotype which is due to the loss of IFNβ-mediated IL-10 expression is observed in WAT of the KO mice compared to that in wild-type mice. Bone-marrow reconstitution experiments demonstrate that the nonhematopoietic cells are the primary contributors to the development of obesity and both hematopoietic and nonhematopoietic cells contribute to the development of obesity-related complications in IRF3 KO mice. This study demonstrates that IRF3 regulates the biology of multiple cell types including adipocytes and macrophages to prevent the development of obesity and obesity-related complications and hence, could be a potential target for therapeutic interventions for the prevention and treatment of obesity-associated metabolic disorders.

Details

Title
Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3
Author
Tang, Peng 1 ; Virtue, Sam 2 ; Goie Jian Yi Gerald 1 ; Png Chin Wen 1 ; Guo, Jing 3 ; Li, Ying 3 ; Jiao Huipeng 1 ; Chua Yen Leong 1 ; Campbell, Mark 2 ; Moreno-Navarrete, José Maria 4 ; Shabbir Asim 5 ; Fernández-Real José-Manuel 4 ; Gasser, Stephan 1 ; Kemeny, David Michael 1 ; Yang, Henry 3 ; Vidal-Puig, Antonio 2 ; Zhang, Yongliang 1 

 National University of Singapore, Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); National University of Singapore, Immunology Programme, Life Sciences Institute, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431) 
 University of Cambridge, Addenbrooke’s Hospital, Institute of Metabolic Science, Wellcome Trust-MRC MDU Metabolic Disease Unit, Cambridge, UK (GRID:grid.120073.7) (ISNI:0000 0004 0622 5016) 
 National University of Singapore, Cancer Science Institute of Singapore, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431) 
 Endocrinology and Nutrition, Institut d’Investigacio Biomedica de Girona (IDIBGI), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn, CB06/03/010), Instituto de Salud Carlos III, and Department of Medical Sciences, Faculty of Medicine, Department of Diabetes, Girona, Spain (GRID:grid.429182.4) 
 National University Hospital, Department of Surgery, Singapore, Singapore (GRID:grid.412106.0) (ISNI:0000 0004 0621 9599) 
Pages
3022-3035
Publication year
2021
Publication date
Nov 2021
Publisher
Nature Publishing Group
ISSN
13509047
e-ISSN
14765403
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2591866961
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.